Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Keros Therapeutics, Inc. - common stock
(NQ:
KROS
)
18.28
+0.49 (+2.75%)
Streaming Delayed Price
Updated: 12:28 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Keros Therapeutics, Inc. - common stock
< Previous
1
2
3
Next >
Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate
↗
December 25, 2025
Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry.
Via
Chartmill
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
↗
June 10, 2025
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.
Via
Benzinga
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
↗
May 29, 2025
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Via
Benzinga
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
↗
April 11, 2025
Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.
Via
Benzinga
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
↗
April 10, 2025
Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control.
Via
Benzinga
Analyst Expectations For Keros Therapeutics's Future
↗
February 27, 2025
Via
Benzinga
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
↗
January 17, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
April 10, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
↗
April 10, 2025
The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control...
Via
Stocktwits
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
↗
April 10, 2025
Via
Benzinga
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
↗
April 10, 2025
Via
Benzinga
Where Keros Therapeutics Stands With Analysts
↗
December 16, 2024
Via
Benzinga
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
November 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 10, 2025
Via
Benzinga
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics
↗
April 01, 2025
Via
Benzinga
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views
↗
January 15, 2025
Via
Benzinga
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results
↗
January 15, 2025
Via
Benzinga
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
↗
January 15, 2025
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.
Via
Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
↗
December 12, 2024
Via
Benzinga
Topics
Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
↗
December 12, 2024
Via
Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
↗
December 12, 2024
Via
Benzinga
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
↗
December 12, 2024
Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025.
Via
Benzinga
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
↗
December 12, 2024
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug.
Via
Investor's Business Daily
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
↗
December 03, 2024
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.
Via
Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
↗
September 05, 2024
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Via
Investor's Business Daily
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
↗
September 03, 2024
Via
Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 03, 2024
Via
Benzinga
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
↗
August 07, 2024
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
